For Immediate Release
Chicago, IL – November 30, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include NVIDIA (
NVDA Quick Quote NVDA - Free Report) , Pfizer ( PFE Quick Quote PFE - Free Report) , Abbott Laboratories ( ABT Quick Quote ABT - Free Report) , United Parcel Service ( UPS Quick Quote UPS - Free Report) and ICICI Bank ( IBN Quick Quote IBN - Free Report) . Here are highlights from Friday’s Analyst Blog: Top Stock Reports for NVIDIA, Pfizer and Abbott
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA, Pfizer and Abbott Laboratories. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>> NVIDIA shares have vastly outperformed the Zacks General Semiconductor industry in the year-to-date period (+127.5% vs. +32.3%), which reflects the company's emergence as an AI and analytics powerhouse on top of its legacy GPU dominance.
It is also benefiting from strong growth in GeForce desktop and notebook GPUs, which is boosting gaming revenues. Moreover, a surge in Hyperscale demand remains a tailwind for the company’s Data Center business. Expansion of NVIDIA GeForce NOW is expected to drive user base. Further, solid uptake of AI-based smart cockpit infotainment solutions is a boon.
Additionally, collaboration with Daimler-owned Mercedes-Benz is expected to further strengthen NVIDIA’s presence in the autonomous vehicles and other automotive electronics space. However, management expects COVID-19 pandemic to negatively impact near-term revenues by $100 million. Moreover, the U.S.-China trade war remains a key concern.
) read the full research report on NVIDIA here >>>
Pfizer have lost -3.7% over the past year against the Zacks Large-Cap Pharmaceuticals industry’s gain of +3.3%. The Zacks analyst believes that the company’s strong portfolio of new drugs will lead to accelerated growth.
The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. The smaller Pfizer should see better revenue growth as the Lyrica loss of exclusivity (LOE) cliff will go away. Pfizer expects strong growth of key brands like Ibrance, Inlyta and Eliquis to drive sales.
The focus remains on whether the FDA grants Emergency Use approval to its COVID-19 vaccine candidate. However, coronavirus-related business disruption hurt sales in Q2 and Q3. The pace of recovery of COVID-19 impact is slower than expected. Meanwhile, currency headwinds and pricing pressure are other top-line headwinds.
) read the full research report on Pfizer here >>> Abbott shares have gained +16.8% over the past six months against the Zacks Medical Products industry’s rise of +7.2%. The Zacks analyst believes that the branded generics and international diabetes businesses should drive growth in the coming quarters. New product launches and acquisitions should boost sales further.
Abbott witnessed double digit organic sales growth and high teens EPS growth in the third quarter of 2020. The company has been seeing improvements in testing and procedure volumes across its hospital-based businesses.
At the same time, its consumer-facing businesses like diabetes care, nutrition and established pharmaceuticals (EPD), are catching up pace following an initial hiccup witnessed during the first few months of the pandemic. In the third quarter, Abbott launched Libre 2 in the United States and obtained CE Mark for Libre 3. In Europe, the company also launched Libre Sense Glucose Sport.
) read the full research report on Abbott here >>>
Other noteworthy reports we are featuring today include United Parcel Service and ICICI Bank.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot stocks we're targeting >>
Join us on Facbook:
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.